Journal of Spine

Introduction: Minimally-invasive transforaminal lumbar interbody fusion offers a conservative surgical option designed to reduce complications. A novel allograft growth factor including multiple factors associated with bone remodeling is utilized and independently assessed for efficacy in supporting fusion.

Case presentation: To evaluate post-surgical follow-up radiology for fusion status of MI-TLIF levels implementing novel allograft growth factor to support bony remodeling

Methods: A fellowship trained orthopedic surgeon collected 102 consecutive studies and was granted a waiver by an Institutional Review Board for retrospective assessment of post-surgical radiology to follow state of fusion.

Results: At three months, 72 of 104 (69.2%) levels assessed were deemed to be fused, at six months 87 of 116 (75.0%) levels assessed were deemed to be fused, at twelve months 107 of 113 (94.7%) levels assessed were deemed to be fused, at eighteen months 107 of 109 (98.2%) levels assessed were deemed to be fused and ultimately at twenty-one months all 108 of 108 (100%) levels reviewed were deemed to be fused.

Conclusion: Novel allograft growth factor demonstrates efficacy with regards to supporting bony fusion with regards to MI-TLIF procedures observed.

Low-back pain (LBP) is a prevalent and complex medical condition that affects individuals of all genders. While LBP is a common complaint, there is a growing body of evidence suggesting that the experience and management of LBP may be influenced by gender-related factors. This article provides a comprehensive review of current concepts related to gender-specific concerns in LBP management. We explore the epidemiology of LBP in different genders, the potential role of sex hormones, psychosocial factors, and healthcare disparities. Understanding these gender-related concerns is crucial for developing more effective and tailored approaches to LBP prevention and treatment.

Central Nervous System (CNS) tumors pose a complex and challenging set of issues for clinicians and patients alike. The advent of MR-linear accelerator technology, which integrates Magnetic Resonance Imaging (MRI) with a linear accelerator for radiation therapy, has opened new possibilities in the treatment of CNS tumors. This article provides a comprehensive review of the current state of practice and future prospects for the combination MR-linear accelerator treatment of CNS tumors. We explore the benefits and challenges, clinical outcomes, technological advancements, and the potential impact on patient care. Understanding the evolving landscape of CNS tumor treatment is essential for healthcare professionals and researchers working in this field. Central Nervous System (CNS) tumors encompass a diverse group of neoplasms that arise in the brain and spinal cord. The treatment of CNS tumors is particularly challenging due to their location, potential for rapid growth, and the need to minimize damage to healthy brain tissue. The integration of Magnetic Resonance Imaging (MRI) with a Linear Accelerator (LINAC) for radiation therapy has given rise to a novel and highly promising approach to CNS tumor treatment.

A 75-year-old male with history of medically controlled Arterial Hypertension (AH) and Parkinson Disease (PD), reporting Degenerative Lumbar Scoliosis and Lumbar Stenosis. Underwent for coronal deformity correction and lumbar stenosis decompression. An immediate successful radiological and clinical outcome, but six weeks after surgical intervention patient with thoracic pain, x-rays showed a fracture of the upper instrumented vertebra. Due to multimorbidity we decided conservative treatment, expecting consolidation. Nevertheless, after 5 months of conservative treatment without bone consolidation, he underwent for a re-intervention, making a transition from a rigid to a semi-rigid spine instrumentation. The purpose of this article is to show how challenging is a combination of PD with Degenerative Spine Disease.